MedCity News

NOVEMBER 14, 2023

Theseus Pharmaceuticals discontinued its former lead program in July following the report of dose-limiting toxicities in two patients. Though Theseus has other assets in its pipeline, it has decided to explore strategic alternatives with the goal of “maximizing shareholder value.”

Leads 108

Leads Pharma Pharmaceutical Patients 108

Pharmaceutical Technology

JUNE 2, 2023

Rentschler Biopharma has collaborated with Ikarovec for expediting the new gene therapies to treat ophthalmic disease. Under the deal, Rentschler Biopharma’s ATMP facility in Stevenage, UK, will undertake the bioprocess development of adeno-associated virus (AAV) material.

Biopharma 52

Biopharma Manufacturing Leads Pharmaceutical 52

Pharmaceutical Technology

MAY 15, 2023

The company’s products Cometriq and Cabometyx are quinoline derivatives developed for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Zhejiang DTRM Biopharma and Oncore Biopharma stand in second and third positions, respectively.

Leads 92

Leads Biopharma Pharmaceutical Pharma 92

European Pharmaceutical Review

AUGUST 24, 2023

This strategy shift did not occur overnight, but evolved in response to the changing biopharma landscape. Even among the leaders of the biopharma sector, few companies have a significant presence across these platforms, Baral highlighted. The post Divest to invest: the new normal in biopharma?

Biopharma 98

Biopharma Pharmaceutical Pharma Medical 98

PM360

OCTOBER 8, 2024

This exciting next phase in Qinecsa’s growth will unlock the wider potential of the combined businesses, following their integration – in the form of new service innovation, expanded market coverage and enhanced patient safety. It was a great honor to be approached to lead Qinecsa’s next important growth phase.

Leads 52

Leads Safety Biopharma Management 52

Pharmaceutical Technology

JANUARY 20, 2023

The demand for mAbs is increasing as they offer patients targeted treatments for a wide range of serious health conditions and diseases. Nevertheless, the potential for mAb therapies in treating medical conditions that have limited options means that biopharma companies are investing considerable resources in development.

Biopharma 52

Biopharma Manufacturing Specialization Engineering 52

MedCity News

JUNE 14, 2023

2seventy Bio reported that an acute myeloid leukemia patient treated with its experimental cell therapy has died, prompting research partner Seattle Children’s Research Institute to pause the Phase 1 study. The FDA has been notified and an investigation is underway.

Leads 95

Leads Patients FDA Biopharma 95

pharmaphorum

AUGUST 5, 2022

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. Such inorganic growth is no longer viable, argues Pervaise Khan, Accenture’s UK Life Sciences Lead. And of course, all of this will feed into future treatments and positive patient outcomes – the sole purpose of pharma.

Biopharma 52

Biopharma Marketing Pharma Relationship management 52

European Pharmaceutical Review

MAY 12, 2023

Swedish Orphan Biovitrum AB (Sobi ® ) has agreed to acquire CTI BioPharma for $1.7 There is a large unmet medical need within myelofibrosis, in particular for patients suffering from thrombocytopenia who are inadequately treated by existing medicines.

Food and Drug Administration 105

Food and Drug Administration Biopharma Medicine Food 105

PM360

AUGUST 9, 2022

Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. For biopharma, success in this space will require integrated models that are significantly different than what has been used with historic medicines. In oncology, it’s 47% less.

Biopharma 69

Biopharma Marketing Healthcare Healthcare 69

Pharmaceutical Technology

SEPTEMBER 8, 2022

Speciality pharmacies play a crucial role in medication dosing, disease and side effects management, and patient care. The expert services rendered by them help in improving patient outcomes, minimising costs of the healthcare system, improving medicinal adherence and persistency and saving clinicians’ time.

Specialization 45

Specialization Leads Pharma Side effects 45

MedCity News

FEBRUARY 12, 2024

FDA approval of Takeda Pharmaceutical drug Eohilia introduces a new therapeutic option for patients with eosinophilic esophagitis, inflammation of the esophagus that causes swallowing difficulty. It will compete against Dupixent, a Sanofi and Regeneron Pharmaceuticals drug already approved for this disorder.

FDA 112

FDA Leads Pharmaceutical Patients 112

pharmaphorum

DECEMBER 16, 2022

The Japanese pharma says it will now start talking to regulatory authorities around the world about potential marketing applications for zolbetuximab as a first-line treatment for patients with locally advanced unresectable or metastatic gastric and gastro-oesophageal (GEJ) cancer. Claudin 18.2 Other companies developing claudin 18.2-targeted

Leads 59

Leads Biopharma Prospecting Patients 59

PM360

JUNE 24, 2024

This fuels an enormous need for effective patient communication and education as new therapies move through the biopharma pipeline. Marketing to rare disease patient populations is equal parts opportunity and responsibility. audiences (direct-to-patient advertising rules are fundamentally different overseas).

Marketing 52

Marketing Patients Food and Drug Administration Digital Media 52

Pharmaceutical Technology

MAY 24, 2023

Amgen develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. Whilst Abliva and Ambrx Biopharma stand in second and third positions, respectively. Merck 42 Unlock company profile C. Menarini Industrie Farmaceutiche Riunite.

Pharmaceutical 52

Pharmaceutical Leads Biopharma Pharmacology 52

PM360

SEPTEMBER 15, 2022

The term “patient centricity” has been around for over a decade, and since its first utterance the buzzword has been praised, dissected, criticized, and everything in between. The concept has always been worthwhile, but people within and outside of the industry have wondered whether the industry was truly becoming more patient centric?

Patients 98

Patients Healthcare Healthcare Marketing 98

European Pharmaceutical Review

APRIL 2, 2024

On his appointment , Wienand, incoming CEO, Lonza shared: “I am very much looking forward to joining Lonza and leading the company into a strong future… [helping to] serve as a partner of choice for the global biopharma industry in its quest to turn breakthrough innovations into viable therapies. billion.

Biopharma 98

Biopharma Leads Manufacturing Pharmaceutical 98

MedCity News

MAY 29, 2023

Ray Therapeutics’ gene therapy is independent of the causative genes driving inherited vision disorders, which CEO Paul Bresge says is important for reaching a broad patient population. Rare disease retinitis pigmentosa is the first disease target, but the startup also plans to test its approach in more prevalent eye disorders.

Leads 106

Leads Patients Biopharma Pharma 106

MedCity News

APRIL 24, 2023

A clinical trial for a Foghorn Therapeutics cancer drug is under a partial FDA hold after a patient in the early-stage study developed a cardiovascular complication. It’s the biotech’s second partial hold in the past year.

FDA 96

FDA Leads Patients Biopharma 96

MedCity News

MARCH 7, 2023

BioMarin Pharmaceutical’s submission of additional data for patients treated with its hemophilia A gene therapy, Roctavian, mean that the FDA will push out a regulatory decision to early summer. But it could be worth the wait as analysts anticipate FDA approval and project Roctavian becoming one of BioMarin’s biggest products.

FDA 101

FDA Leads Pharmaceutical Patients 101

MedCity News

JANUARY 3, 2023

By allowing study teams to design and conduct more inclusive and/or relevant studies, real-world data can enhance the standard of care and ultimately improve patient outcomes.

Recruitment 90

Recruitment Leads Patients Biopharma 90

Pharmaceutical Technology

MAY 15, 2023

BMS is a specialty biopharmaceutical company that is engaged in the discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on oncology, cardiovascular, immunology, and fibrotic therapeutic projects.

Pharmaceutical 52

Pharmaceutical Leads Pharmacology Medicine 52

Pharmaceutical Technology

MAY 15, 2023

Pancrelipase and other pancreatic enzyme products can be administered to at least partially remedy the enzyme deficiency in patients caused by various conditions affecting the pancreas, including pancreatitis and pancreatectomy, as well as diseases such as cystic fibrosis.

Pharmaceutical 52

Pharmaceutical Leads Biopharma Medical 52

European Pharmaceutical Review

SEPTEMBER 27, 2023

Results from Small Pharma’s Phase Ib study in selective serotonin reuptake inhibitor (SSRIs) interaction with SPL026, native N, N-dimethyltryptamine (DMT) has revealed that 92 percent of patients gained remission from major depressive disorder ( MDD ). Currently, SSRIs are the standard of care for MDD.

Pharma 105

Pharma Biopharma Patients Leads 105

Pharmaceutical Technology

MAY 9, 2023

The companies will use the natural product discovery capabilities of Ginkgo Bioworks to expedite the discovery and development of new therapeutic molecules to address diseases with high unmet patient needs.

Biopharma 104

Biopharma Sales Leads Patients 104

Pharmaceutical Technology

APRIL 18, 2023

Compounds that either inhibit or block the activity of glycoside hydrolases are used for the glycaemic control in patients with type 2 diabetes and diseases such as type I Gaucher disease.

Pharmaceutical 52

Pharmaceutical Leads Biopharma Manufacturing 52

MedCity News

JUNE 30, 2022

The FDA placed a partial clinical hold on late-stage tests of Sanofi multiple sclerosis drug tolebrutinib after some patients developed drug-induced liver injury. tests are paused, Sanofi said clinical testing in other countries is continuing with additional safety monitoring.

FDA 101

FDA Leads Safety Patients 101

European Pharmaceutical Review

AUGUST 23, 2023

Retevmo’s potential in oncology The Phase III study LIBRETTO-531 enrolled 291 patients and is the first randomised trial to compare the safety and efficacy of a highly selective RET -kinase inhibitor with multikinase inhibitors in this patient population. More than 800 patients from 16 countries were included in the trial.

Biopharma 98

Biopharma Safety Medical Patients 98

Clarivate

NOVEMBER 13, 2023

Clinical outcome assessments can take years to generate but may pay big dividends in patient-focused drug development, centering the patient experience and potentially bolstering a product’s case with regulators and payers. A clinical outcome assessment is a measure that describes or reflects how a patient feels, functions or survives.

Patients 52

Patients Food and Drug Administration FDA Safety 52

Pharmaceutical Technology

APRIL 20, 2023

CBC CEO Fu Wei stated: “Hasten is a well-established Chinese biopharma company with tremendous growth potential. Hasten will also use the proceeds from the round to fund future acquisitions. The firm reported 47% growth in sales from Q2 to Q4 in 2022, which is testament to CBC’s unique and effective investor-operator strategy.

Biopharma 98

Biopharma Healthcare Healthcare Sales 98

MedCity News

APRIL 21, 2023

The new DEA ruling is doing a disservice not only to people with OUD, but to the entire medical care system—exacerbating a condition that will most likely lead to death.

Physicians 103

Physicians Patients Leads Medical 103

European Pharmaceutical Review

MAY 2, 2024

As a result, the market is expected to reach $719 billion by 2030, 1 Sigma Mostafa, PhD, Chief Scientific Officer at KBI Biopharma shared with EPR. What excites me most is the continuous infusion of new modalities, unique conjugates, and enabling technologies leading to more targeted and effective therapies.

Medicine 105

Medicine Manufacturing Biopharma Engineering 105

MedCity News

AUGUST 6, 2024

Its lead program is on track for Phase 2 testing in immunocompromised Covid-19 patients; a preclinical pan-influenza program is in development under a BARDA contract. Apple Tree Partners’ latest startup is Red Queen Therapeutics, developer of stapled peptide drugs that block viral fusion.

Leads 109

Leads Patients Biopharma Pharma 109

pharmaphorum

JANUARY 6, 2023

From enabling patient choice during clinical trials to strengthening vital partnerships across the quality ecosystem, connected data will become the lifeblood that enables life sciences teams to collaborate efficiently and effectively in 2023. Patient choice will push sponsors toward operational excellence.

Safety 109

Safety Management Patients Training 109

Clarivate

AUGUST 17, 2022

In our latest podcast, Ideas to Innovation, we speak with Dr. Grace Lomax, the clinical director at Patient Connect, part of Clarivate. Supporting patients at the point of care. Making significant strides towards patient access, education and engagement is the mission of Patient Connect. Dr. Grace Lomax.

Healthcare 52

Healthcare Healthcare Patients Physicians 52

pharmaphorum

DECEMBER 23, 2022

In 2022, life sciences companies have been hard at work breaking down silos to better serve patients and healthcare professionals (HCPs). With these silos breaking down, biopharmas will have the opportunity to drive a more coordinated approach to HCP engagement using shared data and unified systems, while still maintaining compliance.

Marketing 99

Marketing Sales Medical Patients 99

Clarivate

NOVEMBER 10, 2022

Clinical outcome assessments can take years to generate but may pay big dividends in patient-focused drug development, centering the patient experience and potentially bolstering a product’s case with regulators and payers. Patient focused drug development in alopecia areata clinical trials.

Patients 52

Patients Food and Drug Administration FDA Safety 52